CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

VOLITIONRX LTD

VNRX
$12M
Micro Cap
NASDAQIn Vitro & In Vivo Diagnostic Substances🇺🇸North AmericaHENDERSON

Drugs in Pipeline

0

Phase 3 Programs

0

Upcoming Catalysts

1

Next Catalyst

Sep 30, 2026

12d

Market Overview

Stock performance and key metrics

VNRX News
Catalyst Timeline

1 upcoming, 0 past

Trial StartNext

Trial Start - DETECSEPS

Sep 30, 2026STALE

VolitionRx reported Q1 revenue of approximately $1M and anticipates enrolling the first DETECSEPS patient in September.

How VNRX's past catalysts played out

earningsAug 2026-14%conference presentationMay 2026-9%OtherApr 2026-9%earningsAug 2025+8%earningsNov 2024-6%earningsMay 2024+6%earningsNov 2023-7%earningsMar 2023-15%
Drug Pipeline

No drugs found in this phase.

sepsis management

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→
Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move
Regulatory Approvals

Frequently asked questions

When is VOLITIONRX LTD's next FDA catalyst?→

VOLITIONRX LTD's (VNRX) next tracked catalyst is a Trial Start expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track VNRX biotech catalysts?→

Add VNRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VOLITIONRX LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply